Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

PURPOSE: Intravenous trastuzumab, pertuzumab, and docetaxel are first-line standard of care for patients with HER2-positive metastatic breast cancer (mBC). MetaPHER is the first study assessing the safety and tolerability of subcutaneous trastuzumab plus intravenous pertuzumab and chemotherapy in a...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Breast Cancer Res Treat
Главные авторы: Kuemmel, Sherko, Tondini, Carlo A., Abraham, Jacinta, Nowecki, Zbigniew, Itrych, Bartosz, Hitre, Erika, Karaszewska, Bogusława, Juárez-Ramiro, Alejandro, Morales-Vásquez, Flavia, Pérez-García, Jose Manuel, Cardona-Huerta, Servando, Monturus, Estefania, Sequi, Marco, Restuccia, Eleonora, Benyunes, Mark, Martín, Miguel
Формат: Artigo
Язык:Inglês
Опубликовано: Springer US 2021
Предметы:
Clinical Trial
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8189949/
https://ncbi.nlm.nih.gov/pubmed/33748921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-021-06145-3
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы